cfDNA in Hereditary And High-Risk Malignancies (CHARM)
Our goal is to improve early cancer detection by developing a blood test to predict cancer development in carriers using circulating DNA. As carriers develop cancer, they may have pre-cancerous cells which release this DNA into the blood (cell-free DNA; cfDNA), which can be detected with novel genetic technologies. We propose to use three complementary cfDNA assays:shallow whole genome sequencing (sWGS), Liquid-Biopsy Sequencing (LB-Seq) and Cell-free Methylated DNA Immunoprecipitation and High-throughput Sequencing (cfMeDip-Seq) for early cancer detection.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001009999 | 28 | ||
| EGAD00001010000 | 30 | ||
| EGAD00001010001 | 23 | ||
| EGAD00001010002 | 173 | ||
| EGAD00001010011 | unspecified | 151 | |
| EGAD00001010013 | unspecified | 174 |
| Publications | Citations |
|---|---|
|
Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.
Cancer Discov 14: 2024 104-119 |
8 |
|
Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns.
Nat Commun 15: 2024 7386 |
0 |